Modeling of the impact of biological drugs in the economic burden of severe asthma
Bronchial asthma (BA) is worldwide lungs’ illness, at least 1,5 mln people are on a dispensary in Russia. Non-control severe BA (SBA) can lead to increasing of direct Health Care System expenditures due to very oft en exacerbations (drugs costs, hospitalizations and out-patient cure etc.) as well as...
Main Authors: | S. K. Zyryanov, I. N. Dyakov, O. I. Karpov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Izdatelstvo OKI
2020-01-01
|
Series: | Качественная клиническая практика |
Subjects: | |
Online Access: | https://www.clinvest.ru/jour/article/view/462 |
Similar Items
-
Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis
by: I. S. Krysanov, et al.
Published: (2020-09-01) -
Dupilumab in the treatment of severe non-control broncial asthma — economic aspects
by: A. S. Salasyuk, et al.
Published: (2019-10-01) -
A social-economic burden of rhinosinusitis with nasal polyps with comorbid asthma and influence of dupilumab
by: I. S. Krysanov, et al.
Published: (2021-12-01) -
Клинико-экономическое обоснование применения Ксолара (омализумаб) при бронхиальной астме
Published: (2018-06-01) -
Cost-effectiveness analysis of the use of mepolizumab in omalizumab-resistant patients with severe asthma
by: A. G. Tolkushin, et al.
Published: (2019-08-01)